Literature DB >> 29108786

Early Phase Clinical Trial Designs - State of Play and Adapting for the Future.

J A Harrington1, T C Hernandez-Guerrero1, B Basu2.   

Abstract

The process of anti-cancer drug development is complex, with high attrition rates. Factors that may optimise this process include well-constructed and relevant pre-clinical testing and use of biomarkers for patient selection. However, the design of early phase clinical trials will probably play a vital role in both the robust clinical investigation of new targeted therapies and in streamlining drug development. In this overview, we assess current concepts in phase I clinical trials, highlighting issues and opportunities to improve their meaningfulness. The particular challenge of how to design combination trials is addressed, with focus on the potential of new adaptive and model-based designs. Crown
Copyright © 2017. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adaptive design; biomarker; dose escalation methods; early phase clinical trials; phase I trials

Mesh:

Substances:

Year:  2017        PMID: 29108786     DOI: 10.1016/j.clon.2017.10.005

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  8 in total

1.  Occurrence of Type 1 Diabetes in A Patient Enrolled in An Immunotherapy Combination Phase 1 Clinical Trial: A Case Study.

Authors:  Sheena Charles; Anna Poullard
Journal:  Asia Pac J Oncol Nurs       Date:  2021-04-24

2.  Transcranial direct current stimulation improves quality of life and physical fitness in diabetic polyneuropathy: a pilot double blind randomized controlled trial.

Authors:  Galeno Ferreira; Edson Silva-Filho; Antônio de Oliveira; Clemilda de Lucena; Johnnatas Lopes; Rodrigo Pegado
Journal:  J Diabetes Metab Disord       Date:  2020-03-14

Review 3.  New clinical trial designs in the era of precision medicine.

Authors:  Elena Garralda; Rodrigo Dienstmann; Alejandro Piris-Giménez; Irene Braña; Jordi Rodon; Josep Tabernero
Journal:  Mol Oncol       Date:  2019-02-22       Impact factor: 6.603

Review 4.  Molecular profiling for precision cancer therapies.

Authors:  Eoghan R Malone; Marc Oliva; Peter J B Sabatini; Tracy L Stockley; Lillian L Siu
Journal:  Genome Med       Date:  2020-01-14       Impact factor: 11.117

5.  Trends in patient-reported outcome use in early phase dose-finding oncology trials - an analysis of ClinicalTrials.gov.

Authors:  Julia Lai-Kwon; Zhulin Yin; Anna Minchom; Christina Yap
Journal:  Cancer Med       Date:  2021-10-22       Impact factor: 4.452

6.  Core values of patients with advanced cancer considering participation in an early-phase clinical trial: a qualitative study.

Authors:  Jelle L P van Gurp; Liza G G van Lent; Nicole Stoel; Carin C D van der Rijt; Maja J A de Jonge; Saskia M Pulleman; Julia C M van Weert; Jeroen Hasselaar
Journal:  Support Care Cancer       Date:  2022-06-08       Impact factor: 3.359

7.  Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum.

Authors:  Julia Lai-Kwon; Alyssa M Vanderbeek; Anna Minchom; Olalekan Lee Aiyegbusi; Della Ogunleye; Richard Stephens; Melanie Calvert; Christina Yap
Journal:  Oncologist       Date:  2022-09-02       Impact factor: 5.837

Review 8.  The Contribution of Clinical Pharmacologists in Precision Medicine: An Opportunity for Health Care Improvement.

Authors:  Davide Grisafi; Alessandro Ceschi; Veronica Avalos Clerici; Francesco Scaglione
Journal:  Curr Ther Res Clin Exp       Date:  2021-04-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.